 Results from phase 12 BRILLIANCE study using EDIT-101 Cas9 nuclease for the treatment of patients with Leber Congenital Amaurosis 10 expected 2nd half of 2022. Results from the phase 12 RUBY study using EDIT-301 AsCas12a nuclease for the treatment of patients with sickle cell disease are expected by end of 2022. 